Drug FDA Class II Terminated Failed specifications
Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-079-93
Viatris Inc Published Jan 22, 2025
Risk level
Class IIMay cause a temporary or reversible health problem; slight chance of serious harm.
Severity score 55/100
What should you do?
- Check whether you have this product, using the lot codes, UPCs, and dates listed below.
- Do not eat, serve, or sell the affected product.
- Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
- Contact Viatris Inc or your place of purchase with questions, and see the source record below for full details.
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Hazards
Impurity Compound B - Out of Specification · primary
Affected products (1)
Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-079-93
CARDURA · 1,215/30 count bottles
NDC: 58151-078, 58151-079, 58151-078-93, 58151-079-93
Lot codes: 8181625
Code info: Lot # 8181625, Exp 12/31/2025
Affected areas
Nationwide
Timeline
- InitiatedDec 23, 2024
- PublishedJan 22, 2025
- TerminatedNov 12, 2025
- Recall number
- D-0203-2025
- Agency
- U.S. Food and Drug Administration
- Country
- US
FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.